Q1 2026 Autolus Therapeutics PLC Earnings Call Transcript

May 14, 2026 / 12:30 PM GMT

Release Date Price: $1.59 (-7.02%)

Transcript 10-Q8-K

Key Points

Positve

Autolus Therapeutics PLC (AUTL) reported a significant increase in revenue for Q1 2026, reaching $26.2 million compared to $9 million in Q1 2025.
The company achieved a positive gross margin for the first time, indicating improved operational efficiency and cost management.
AUTL has expanded its market presence with over 73 centers in the U.S. and more than 10 active centers in the U.K., with plans to exceed 80 centers by year-end.
The company is seeing positive physician experiences and strong patient outcomes, with a 90% overall response rate and a favorable safety profile.
AUTL is actively expanding its clinical trials and development programs, including studies in pediatric populations and new indications such as lupus nephritis and multiple sclerosis.

Negative

Despite revenue growth, AUTL reported a net loss of $71.6 million for Q1 2026, slightly higher than the $70.2 million loss in Q1 2025.
The company's cash reserves decreased from $300.7 million at the end of 2025 to $229.4 million by March 31, 2026, due to operational expenses.
AUTL's selling, general, and administrative expenses increased significantly to $39.9 million in Q1 2026, up from $29.5 million in Q1 2025.
The company has undergone a reduction in force by 13% as part of its operational efficiency and cost reduction initiatives.
AUTL faces challenges in market expansion, particularly in Europe, where market access and reimbursement negotiations are ongoing and complex.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AUTL.OQ - Autolus Therapeutics PLC
Q1 2026 Autolus Therapeutics PLC Earnings Call
May 14, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day, everyone, and welcome to Autoloss Therapeutics' First Quarter 2026 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the presentation, there will be a question-and-answer session. To ask a question, you will need to press *11 on your telephone. You will then hear a message advising your hand is raised. To withdraw your question, please press *11 again. Please be advised that today's conference is being recorded. I would now like to turn the call over to the Executive Director of Investor Relations, Amanda Cray. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.